The effect of two selective A
Adenosine
/ analogs & derivatives
Adenosine A1 Receptor Agonists
/ pharmacology
Adenosine A2 Receptor Agonists
/ pharmacology
Aminopyridines
/ pharmacology
Animals
Cardiovascular System
/ drug effects
Consciousness
Drug Partial Agonism
Heart Rate
/ drug effects
Hemodynamics
/ drug effects
Ligands
Male
Rats, Sprague-Dawley
Receptor, Adenosine A1
/ drug effects
Receptor, Adenosine A2A
/ drug effects
Receptor, Adenosine A2B
/ drug effects
Regional Blood Flow
/ drug effects
Thiazoles
/ pharmacology
Thiophenes
/ pharmacology
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
26
02
2019
revised:
05
09
2019
accepted:
10
09
2019
pubmed:
10
10
2019
medline:
20
4
2021
entrez:
10
10
2019
Statut:
ppublish
Résumé
Adenosine is a local mediator that regulates physiological and pathological processes via activation of four GPCRs (A The regional haemodynamic responses of these agonist was investigated in conscious rats. Male Sprague-Dawley rats (350-450 g) were chronically implanted with pulsed Doppler flow probes on the renal, mesenteric arteries and the descending abdominal aorta and the jugular vein and caudal artery catheterized. Cardiovascular responses were measured following intravenous infusion (3 min each dose) of CCPA (120, 400, and 1,200 ng·kg CCPA produced a significant A These results suggest VCP746 mediates its cardiovascular effects via activation of A
Sections du résumé
BACKGROUND AND PURPOSE
Adenosine is a local mediator that regulates physiological and pathological processes via activation of four GPCRs (A
EXPERIMENTAL APPROACH
The regional haemodynamic responses of these agonist was investigated in conscious rats. Male Sprague-Dawley rats (350-450 g) were chronically implanted with pulsed Doppler flow probes on the renal, mesenteric arteries and the descending abdominal aorta and the jugular vein and caudal artery catheterized. Cardiovascular responses were measured following intravenous infusion (3 min each dose) of CCPA (120, 400, and 1,200 ng·kg
KEY RESULTS
CCPA produced a significant A
CONCLUSIONS AND IMPLICATIONS
These results suggest VCP746 mediates its cardiovascular effects via activation of A
Identifiants
pubmed: 31596949
doi: 10.1111/bph.14870
pmc: PMC6989947
doi:
Substances chimiques
Adenosine A1 Receptor Agonists
0
Adenosine A2 Receptor Agonists
0
Adora2b protein, rat
0
Aminopyridines
0
Ligands
0
Receptor, Adenosine A1
0
Receptor, Adenosine A2A
0
Receptor, Adenosine A2B
0
Thiazoles
0
Thiophenes
0
VCP746
0
2-chloro-N(6)cyclopentyladenosine
37739-05-2
Adenosine
K72T3FS567
capadenoson
O519NVW73R
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
346-359Subventions
Organisme : Medical Research Council
ID : MR/N020081/1
Pays : United Kingdom
Organisme : Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES)-University of Nottingham Programme in Drug Discovery Postdoctoral Fellowship
ID : 88881.141266/2017-01
Pays : International
Organisme : British Heart Foundation
ID : PG/14/95/31248
Pays : United Kingdom
Informations de copyright
© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Neuropharmacology. 2011 Jan;60(1):24-35
pubmed: 20637785
Circ Res. 1970 Mar;26(3):327-38
pubmed: 4313452
Pharmacol Ther. 2013 Oct;140(1):92-111
pubmed: 23764371
J Cardiovasc Pharmacol. 1997 Sep;30(3):320-4
pubmed: 9300315
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Clin Res Cardiol. 2012 Jul;101(7):585-91
pubmed: 22370739
Mol Pharmacol. 2010 Sep;78(3):444-55
pubmed: 20547736
Brain Res Bull. 1988 Jan;20(1):129-32
pubmed: 3342338
Drug Discov Today Technol. 2013 Summer;10(2):e285-96
pubmed: 24050280
Biochim Biophys Acta. 2011 May;1808(5):1309-18
pubmed: 20599682
Neuropharmacology. 2014 Jun;81:6-14
pubmed: 24486382
Neuropharmacology. 2015 Nov;98:68-77
pubmed: 25937210
ChemMedChem. 2017 May 22;12(10):728-737
pubmed: 28488817
Hypertension. 1986 May;8(5):391-8
pubmed: 3699881
J Med Chem. 2010 Sep 23;53(18):6550-9
pubmed: 20806896
Mol Pharmacol. 2015 Sep;88(3):460-8
pubmed: 26104547
Br J Pharmacol. 2020 Jan;177(2):346-359
pubmed: 31596949
Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359
pubmed: 29055034
Purinergic Signal. 2012 Feb;8(Suppl 1):91-9
pubmed: 22081230
Br J Pharmacol. 2014 Mar;171(5):1102-13
pubmed: 24024783
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4614-9
pubmed: 24619092
J Cardiovasc Pharmacol. 1992 Mar;19(3):460-3
pubmed: 1378130
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Biochim Biophys Acta. 2011 May;1808(5):1290-308
pubmed: 21185259
Neuroscience. 2000;95(2):513-8
pubmed: 10658631
Br J Pharmacol. 2005 Mar;144(5):642-50
pubmed: 15678095
Br J Pharmacol. 2010 Aug;160(7):1573-6
pubmed: 20649560
J Med Chem. 2018 Mar 8;61(5):2087-2103
pubmed: 29446948
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
Br J Pharmacol. 2017 Dec;174 Suppl 1:S17-S129
pubmed: 29055040
FASEB J. 2017 Mar;31(3):1193-1203
pubmed: 27986807
J Med Chem. 2009 Jul 23;52(14):4543-7
pubmed: 19514747
Pharmacol Rev. 2011 Mar;63(1):1-34
pubmed: 21303899
Clin Exp Pharmacol Physiol. 2016 Oct;43(10):976-82
pubmed: 27377874
Biochim Biophys Acta. 2011 May;1808(5):1413-28
pubmed: 21094127
Biochem Pharmacol. 2016 Oct 1;117:46-56
pubmed: 27520486
Br J Pharmacol. 2019 Apr;176(7):864-878
pubmed: 30644086
J Cell Physiol. 2007 Dec;213(3):785-92
pubmed: 17516542
Annu Rev Pharmacol Toxicol. 1991;31:1-35
pubmed: 2064369
Br J Pharmacol. 2008 Aug;154(8):1600-10
pubmed: 18500354
J Pharmacol Exp Ther. 1987 Sep;242(3):882-7
pubmed: 3656117
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986